HypoBar I: Delaying intestinal glucose absorption to ameliorate post-bariatric hypoglycaemia. A randomized cross-over clinical trial.
Latest Information Update: 24 Nov 2024
At a glance
- Drugs Acarbose (Primary) ; Canagliflozin (Primary)
- Indications Hypoglycaemia
- Focus Therapeutic Use
- Acronyms HypoBar I
Most Recent Events
- 24 Apr 2024 Status changed from recruiting to discontinued.
- 13 Sep 2022 New trial record